Universal vaccine approaches for current SARS-CoV-2 variants and future coronaviruses in LMICs

针对中低收入国家当前 SARS-CoV-2 变种和未来冠状病毒的通用疫苗方法

• 批准号: 450262
• 负责人: Kelvin Alyson A
• 金额: $ 14.2万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-07-01 至 2023-07-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=450262&lang=en
• 关键词: Broadly Neutralizing Antibodies; Broadly Reactive T Cells; Coronaviruses; Covid-19; Covid-19 Vaccines; Pan Coronavirus Vaccines; Sars-Cov-2; Sars-Cov-2 Variants; T Cells; Universal Vaccines; Broadly Neutralizing Antibodies; Broadly Reactive T Cells; Coronaviruses; Covid-19; Covid-19 Vaccines; Pan Coronavirus Vaccines; Sars-Cov-2; Sars-Cov-2 Variants; T Cells; Universal Vaccines

The COVID-19 (coronavirus disease 2019) pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2 or SARS2) has significantly impacted global public health and wellbeing. Newly developed COVID-19 vaccines protect against infection o

严重的急性呼吸综合征冠状病毒（SARS-COV-2或SARS2）引起的Covid-19（2019年冠状病毒疾病）大流行对全球公共卫生和福祉产生了重大影响。新开发的Covid-19疫苗可预防感染O